Details of the Drug

General Information of Drug (ID: DMYHN59)

Drug Name
Axicabtagene ciloleucel
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Approved [1]
Large B-cell lymphoma 2A81 Approved [2]
Follicular lymphoma 2A80 Phase 2/3 [3]
Mantle cell lymphoma 2A85.5 Phase 2/3 [4]
Primary mediastinal B-cell lymphoma 2A81 Phase 2/3 [3]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Acute lymphoblastic leukaemia 2A85 Phase 1 [4]
⏷ Show the Full List of Indication(s)
Affected Organisms
Humans and other mammals
ATC Code
L01XL03: Axicabtagene ciloleucel
L01XL: Antineoplastic cell and gene therapy
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
CAR T Cell Therapy
Cross-matching ID
UNII
U2I8T43Y7R
DrugBank ID
DB13915
TTD ID
D0DK5R
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Diffuse large B-cell lymphoma
ICD Disease Classification 2A81
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)